Pharmaceutical Pipeline


Amorphical has managed to successfully synthesize and produce nanoparticulate amorphous calcium carbonate (ACC) having log-term stability. Amorphical’s ACC is the only non-crystalline calcium supplement in the world. The stabilized ACC technology is based on biomimicry of the gastrolith in which the blue crayfish stores stabilized ACC, allowing it to regenerate its exoskeleton (one-third of its body mass) within merely 3 days – a process that takes for other crustaceans about one month. Amorphical has proven that ACC’s solubility, bioavailability and fractional absorption are far superior compared to other calcium products, including products of the world’s leading companies.

Cancer is the general name for a group of diseases involving uncontrolled growth of cells which had mutated to form a malignant tumor able to invade or spread to other parts of the body. A cancerous tumor creates a new system of blood supply in the tumor area and has an ability for accelerated growth and evading attacks by the body’s immune system.

For years, Amorphical’s scientists have been researching the uses of ACC for its potential as an anti-inflammatory and anti-cancer therapy. Following a series of experimental observations, they began to study ACC’s ability to successfully treat cancer due to its ability to regulate pH levels in acidic environments, in which cancer cells flourish and spread. In multiple preclinical studies conducted by Amorphical, ACC activity was repeatedly found to be directly associated with anti-cancer activity.

Below is a summary of the preclinical studies performed by Amorphical and the influence of ACC on cancer:


1. Glycolysis: One of the characteristics of cancer is the shift of the cellular metabolic pathway (processing of glucose into energy) from oxidative phosphorylation to glycolysis, in which hydrogen ions (protons) are released, making the environment more acidic. A study performed with murine breast cancer cells showed that treatment with ACC suppresses glycolysis in cancer cells and increases the rate of oxidative phosphorylation. This change does not occur in the presence of other calcium sources (crystalline calcium carbonate (CCC) or calcium chloride (CaCl2).


2. Differential gene expressions indicating strengthening the immune system and inhibiting cancer activity: The addition of ACC to various human cancer cell cultures was found to up- or downregulate multiple gene expressions in a way, which promotes an anti-carcinogenic phenotype associated with reduced proliferation rates and enhanced immune-system ability to fight cancer cells. Various influences of this sort were found for the following cell lines: acute myeloid leukemia, prostate, lung, breast (two lines—(1)triple negative and (2) hormone positive cells), colorectal cancer and cervical cancer cells.


3. Increased survival and reduction of tumor growth rate: In preclinical studies of breast cancer with bone metastases, the survival rates of animals treated with ACC were higher compared to control animals.
Other studies done with a subcutaneous model of lung cancer (Lewis Lung Carcinoma) in mice showed that tumors growth rates decreased significantly compared to the control group. In a xenograft study in which human lung cancer cells were injected into nude mice (mice with a compromised immune system), tumor’s growth rates of the ACC-treated mice were significantly lower relative to the control animals.


4. Reduction of the enzymatic activity of Cathepsin B: Cathepsin B is an enzyme that helps cancerous tumors grow and spread to other parts of the body (metastasize). Acidic environments and high levels of Cathepsin B are associated with tumor advancement, creation of metastases and development of associated inflammations. Cathepsin B activity was assessed in mice with subcutaneous Lewis lung carcinoma (in tandem with the reduced tumor’s growth rates) that were treated with ACC compared to control mice. The results showed a significant reduction in the Cathepsin B activity of the ACC-treated mice groups compared to the control group.


Amorphical Strives to Revolutionize Cancer Treatment

Our preclinical studies have demonstrated ACC’s ability to regulate low pH in tumor’s microenvironment, inhibiting the tumor growth.

In summary, the combined studies indicate that ACC:

1. Regulates acidity in inflammatory environment,

2. Improves/enhances immune response against the tumors and malignant cells,

3. Reduces the activity of Cathepsins (especially Cathepsin B, which helps tumors metastasize),

4. May slow down and alter the evolution of new blood vessels, hence increasing nutrition to the tumor cells,

5. Changes cancer cells’ metabolism towards oxidative phosphorylation, and

6. Shifts the cancer cells’ genetic expressions in modes that suppress the malignant activities and the resistance to the immune system of the body.

Amorphical’s initial clinical trials in patients with various types of terminal cancer who had exhausted every other available treatment option have also indicated that ACC has anti-cancer potential, and that it is a safe treatment even in high doses and does not exhibit the severe and traumatic side effects of standard cancer therapies.

Encouraged by these initial results, Amorphical is planning to conduct additional controlled clinical studies with a larger groups of advanced cancer patients, for a more extensive examination of ACC’s potential in specific types of cancer. The anticipated successful studies will lead to novel treatments that will revolutionize the world of healthcare.

For more information, please contact us.

Skip to content